Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.…
Mereo BioPharma Reports Third Quarter 2026 Financial Results
Mereo BioPharma Group (NASDAQ: MREO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 39 employees.
The shares were at 0.2600 USD on 20 November 2026, down 85.9% over 52 weeks. Its 52-week range is 0.2000 USD to 2.370 USD: the price is 89.0% below the high and 30.0% above the low.
Its market capitalisation is 41.52M USD.
Mereo BioPharma Group reports return on equity of -102.4%.
It holds more cash than debt, a net cash position of 25.52M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.